Elevated cardiac troponin I, creatine kinase and myoglobin and their relationship with cardiovascular risk factors in patients with type 2 diabetes

Odum, Ehimen P.; Young, Ekenechukwu

doi:10.1016/j.dsx.2017.12.001

Cited by 30 publications

(17 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results the The results presented in the current study demonstrates a significant elevation in the serum levels of creatine kinase (CK), which is in line with many previous studies [26,27,28,29]. In diabetes patients, disturbance in the metabolism of glucose, lipids and proteins occurs at the level of muscular cells.…”

Section: Serum Levels Of Cardiac Function Markerssupporting

confidence: 92%

Alterations of Obestatin, Cardiac Markers and Lipid Profile Levels in Type 2 Diabetes Mellitus

Balaky¹,

Kakey

2021

eijs

View full text Add to dashboard Cite

The current investigation aimed to test the alterations of the levels of obestatin hormone, lipid profile and cardiac function markers in relation to hyperglycemia in patients with non-insulin diabetes mellitus. The study included 118 diabetic subjects (56 males, 62 females) and 60 healthy non-diabetic subjects (30 males, 30 females). Diabetic and healthy subjects were age-matched. Serum levels of obestatin, lipid profile markers including total cholesterol (STC), triglycerides (STG), low and high density lipoproteins (LDL-C and HDL-C), as well as cardiac function markers including, creatine kinase and lactate dehydrogenase enzymes were determined in all subjects. The findings revealed a remarkable decrease in the level of serum obestatin in both diabetic males and females with both age ranges (40-59 and 60-80 years). On the other hand, the results showed that serum STC, LDL-C, and STG levels were statistically significantly elevated, while that for HDL-C was significantly decreased in diabetic males and females with both age ranges. Concerning the cardiac markers, the results found out that the levels of CK-MB and LDH were significantly increased in type 2 diabetic males and females with both age ranges. The results suggested that a low concentration of obestatin is a significant risk factor for type 2 DM, with a key role for this hormone in the pathogenesis. Accordingly, altered levels of obestatin could be used as an important indicator for type 2 DM. The current study also suggests a direct relationship between lipid profiles, except for HDL, the decreased obestatin level, the increased cardiac function markers, and hyperglycemic status in type 2 DM.

show abstract

Section: Serum Levels Of Cardiac Function Markerssupporting

confidence: 92%

Alterations of Obestatin, Cardiac Markers and Lipid Profile Levels in Type 2 Diabetes Mellitus

Balaky¹,

Kakey

2021

eijs

View full text Add to dashboard Cite

show abstract

“…In the present study, CK-MB levels were not altered in the CTZ group, but were increased in the ASA group, leading to a significant difference between the two groups. Given that CK-MB is a marker of myocardial damage 31 and its subclinical elevation in patients with T2DM, 32 these results suggest that CTZ but not ASA treatment may mitigate myocardial damage.…”

Section: Figurementioning

confidence: 83%

Effect of cilostazol, a phosphodiesterase‐3 inhibitor, on coronary artery stenosis and plaque characteristics in patients with type 2 diabetes: ESCAPE study

Lee

Chun

et al. 2019

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim: To perform a prospective study to evaluate the effect of cilostazol (CTZ) compared with aspirin (acetylsalicylic acid; ASA) in Korean people with diabetes and subclinical coronary atherosclerosis.Materials and methods: A total of 100 people with diabetes who had mild to moderate coronary atherosclerosis, assessed by coronary computed tomographic angiography (CCTA), were randomly assigned to either 200 mg/d CTZ or 100 mg/d ASA (n = 50 each group). The primary outcome was change in coronary artery stenosis assessed by CCTA after 12 months of treatment. Secondary outcomes included changes in plaque composition, coronary artery calcium score and cardiac markers.Results: The mean age, body mass index and glycated haemoglobin concentration were 61.5 years, 25.0 kg/m 2 and 56.8 mmol/mol, respectively, and were well matched between the two groups. Coronary artery stenosis decreased in the CTZ group (from 44.0 ± 2.1% to 40.4 ± 2.5%) but remained unchanged in the ASA group (from 38.9 ± 2.1% to 40.6 ± 2.1%). In the CTZ group, the non-calcified portion of plaques decreased significantly (from 20.6 ± 3.0 to 17.3 ± 3.0 mm 3 ), whereas it did not change significantly in the ASA group (15.2 ± 2.8 vs 16.6 ± 2.9 mm 3 ). Increases in HDL cholesterol, decreases in triglycerides, liver enzyme and high-sensitivity C-reactive protein levels, and reductions in abdominal visceral fat area and insulin resistance were observed only in the CTZ group.Conclusion: CTZ treatment for 12 months decreased coronary artery stenosis and the noncalcified plaque component. These results suggest that CTZ treatment may be an option for preventing the progression of coronary atherosclerosis in people with diabetes.

show abstract

“…Mb mainly exists in the striated muscle, which is a polypeptide chain widely distributed in myocardial and skeletal muscle tissues (17). As a small-molecule protein containing heme, Mb can display the tissue hypoperfusion and oxygenation dysfunction, so its level increases in the case of shortness of breath or chest pain in patients with myocarditis (18). Related studies (19) have demonstrated that if patients suffer from severe myocardial damage or ventricular systolic dysfunction, the level of Mb is increased, which has a significantly positive correlation with the degree of degeneration or necrosis of myocardial cells.…”

Section: Discussionmentioning

confidence: 99%

Application value of hypersensitive C-reactive protein, lactic acid and myoglobin in the combined detection of myocarditis

et al. 2019

View full text Add to dashboard Cite

Application value of hypersensitive C-reactive protein (hs-CRP), blood lactic acid (LAC) and myoglobin (Mb) in the combined detection of myocarditis was explored. A total of 107 patients with suspected myocarditis treated in The Second Nanning People's Hospital from January 2015 to December 2017 were retrospectively analyzed, of whom 81 patients diagnosed with myocarditis were enrolled into the research group, and 26 non-myocarditis individuals were enrolled into the control group. Fasting venous blood was drawn from all patients to detect the hs-CRP, LAC and Mb, and their levels were compared and analyzed between the two groups. Moreover, the coincidence rate, sensitivity and specificity of single detection and combined detection by hs-CRP, LAC and Mb in the diagnosis of myocarditis were compared and analyzed. There were no significant differences in the sex, age, smoking status, alcohol consumption, chest distress, palpitation, angina and dyspnea between the two groups (P>0.05), proving that patients in both groups were comparable. The levels of hs-CRP, LAC and Mb in the research group were significantly higher than those in the control group, displaying statistically significant differences (P<0.05). According to the receiver operating characteristic (ROC) curve, the area under the curve (AUC), coincidence rate, sensitivity and specificity in the diagnosis of myocarditis, respectively, were 0.610 (95% CI: 0.495–0.725), 58.88, 51.85 and 80.77% for hs-CRP, 0.657 (95% CI: 0.551–0.763), 58.88, 54.32 and 73.08% for LAC, 0.747 (95% CI: 0.651–0.843), 69.16, 64.20 and 84.62% for Mb, and 0.773 (95% CI: 0.680–0.867), 76.64, 79.01 and 69.23% for combined detection. Hs-CRP, LAC and Mb are highly expressed in the serum of patients with myocarditis, and their combined detection has guiding significance for the prevention and treatment of myocarditis.

show abstract

Elevated cardiac troponin I, creatine kinase and myoglobin and their relationship with cardiovascular risk factors in patients with type 2 diabetes

Cited by 30 publications

References 18 publications

Alterations of Obestatin, Cardiac Markers and Lipid Profile Levels in Type 2 Diabetes Mellitus

Alterations of Obestatin, Cardiac Markers and Lipid Profile Levels in Type 2 Diabetes Mellitus

Effect of cilostazol, a phosphodiesterase‐3 inhibitor, on coronary artery stenosis and plaque characteristics in patients with type 2 diabetes: ESCAPE study

Application value of hypersensitive C-reactive protein, lactic acid and myoglobin in the combined detection of myocarditis

Contact Info

Product

Resources

About